Boosting the Immune System to Fight Breast Cancer
Targeting cellular double-stranded RNA homeostasis in breast cancer
This research explores a new way to make breast cancer tumors more visible to the body's immune system, helping it fight the cancer more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgetown University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-11121763 on NIH RePORTER |
What this research studies
Many breast cancers are 'cold' tumors, meaning they don't trigger a strong immune response from the body. Our bodies naturally have double-stranded RNAs (dsRNAs) inside cells, and sometimes too much of these can alert the immune system. This project looks at a specific protein, DDX3X, in breast cancer cells. By blocking DDX3X, we can cause these dsRNAs to build up, which then signals the immune system. This signal helps the immune system recognize and attack the cancer cells more effectively, potentially making immunotherapies work better.
Who could benefit from this research
Good fit: This research is focused on understanding breast cancer at a cellular level, particularly for patients with tumors that are not currently responsive to immunotherapy.
Not a fit: Patients whose tumors already respond well to current immunotherapies may not see additional benefit from this specific approach.
Why it matters
Potential benefit: If successful, this approach could make existing immunotherapies more effective for breast cancer patients whose tumors currently don't respond well.
How similar studies have performed: While the concept of using cellular dsRNAs to trigger immune responses is gaining interest, this specific strategy of targeting DDX3X to achieve this in breast cancer is a novel area of exploration.
Where this research is happening
Washington, United States
- Georgetown University — Washington, United States (Active)
Researchers
- Principal investigator: Han, Cecil — Georgetown University
- Study coordinator: Han, Cecil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.